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Abstract
Background: Optimal treatment for established renal failure is living donor kidney transplantation. However this
pathway exposes healthy individuals to significant reduction in nephron mass via major surgical procedure.
Laparoscopic donor nephrectomy is now the most common method for live donor transplantation, reducing both
donor post-operative pain and recovery time. However this procedure exposes kidneys to additional
haemodynamic stresses. It has been suggested that donor hydration—particularly the use of preoperative
intravenous fluids—may counteract these stresses, reducing subclinical acute kidney injury and ultimately
improving long-term renal function. This may be important in both preservation of donor renal function and
recipient graft longevity.
Methods/Design: A prospective single-centre single-blinded randomized controlled trial will be carried out to
determine the effects of donor preoperative intravenous fluids. The primary outcome is donor subclinical acute
kidney injury (defined as plasma NGAL, >153 ng/ml) on day 1 postoperatively. Secondary outcomes include
intraoperative haemodynamics, recipient subclinical acute kidney injury, perioperative complications and donor
sleep quality.
Donors will be randomised into two groups: the intervention group will receive active pre-hydration consisting of
three litres of intravenous Hartmann’s solution between midnight and 8 am before morning kidney donation, while
the control group will not receive this. Both groups will receive unlimited oral fluids until midnight, as is routine.
Plasma NGAL will be measured at pre-specified perioperative time points, intraoperative haemodynamic data will
be collected using non-invasive cardiac output monitoring and clinical notes will be used to obtain demographic
and clinical data. The researcher will be blinded to the donor fluid hydration status. Blinded statistical analysis will
be performed on an intention-to-treat basis. A prospective power calculation estimates a required sample size of 86
patients.
Discussion: This study will provide important data, as there is currently little evidence about the use of donor
preoperative fluids in laparoscopic nephrectomy. It is hoped that the results obtained will guide future clinical
practice.
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Background
Chronic Kidney Disease and Renal Transplant
Chronic kidney disease (CKD) has an estimated prevalence
of 8.5% in the UK adult population [1]. A small but signifi-
cant proportion of patients develop end stage renal disease
(ESRD) [2]—irreversibly reduced renal function where renal
replacement therapy, either dialysis or transplant, is required
for survival [3–5]. Currently around 4800 patients in Scotland
are on some form of renal replacement therapy, with over
50% of these patients having received a renal transplant [6].
Renal transplantation is associated with increased life
expectancy and quality of life compared to dialysis and so
should be considered in all patients with ESRD [7, 8].
However, there is an intense kidney shortage (the average
UK renal transplant waiting time for a cadaveric kidney is
3–4 years [9]). Almost 300 people die in the UK each year
while waiting for a kidney transplant, and many more are
removed from the waiting list, having become too ill for a
transplant [10]. Therefore, everything possible must be
done to maximise renal transplant benefit, particularly the
benefit of living donation which is associated with super-
ior graft and patient survival [11].
The price of better recipient outcomes with living kidney
donation is some associated additional donor risk [12].
Earlier studies suggested that kidney donation does not
affect mortality [13] but a recent prospective observational
study by Mjøen et al. [14], comparing kidney donors with
carefully matched controls and longer follow-up periods
found kidney donation to be associated with a 30% increase
in the relative risk of all-cause mortality over a long follow
up period (more than 20 years). Furthermore, Muzaale et
al. [15] estimated the lifetime risk of ESRD to be 0.9% in liv-
ing kidney donors, compared with 0.14% in healthy non-
donors. Ethically everything possible must be done to pre-
serve renal function in this group, who are undertaking
these risks for no personal health benefit.
Pneumoperitoneum, Renal Perfusion and Subclinical
Acute Kidney Injury
First carried out in 1995, laparoscopic nephrectomy is
now widespread and has resulted in increasing live
donor transplantation [16]. Despite reducing post-
operative pain and speeding up recovery, the tech-
nique exposes the kidney to theoretical additional
haemodynamic stresses of extremes of posture for op-
timal access and pneumoperitoneum [17].
The effect of increased intra-abdominal pressure is
well characterized in abdominal compartment syndro-
me—organ dysfunction secondary to intra-abdominal
hypertension, defined as ≥12 mm Hg [18]. Pneumoperi-
toneum usually uses pressures of between 12–15 mmHg.
The kidneys are particularly sensitive to haemodynamic
changes [19]. Studies have shown a decrease in renal
blood flow and renal function associated with pneumo-
peritoneum, though as renal function returns to normal
afterwards this phenomenon has been deemed of “un-
certain clinical significance” [20, 21]. Indeed a recent
Cochrane review found no difference in kidney function
in open vs laparoscopic nephrectomy at 1 year [22].
This may reflect the fact that the kidneys have a large
reserve, with approximately 50% of renal parenchyma
compromise needed to see changes in eGFR. Therefore,
even if renal damage has taken place, it may not be de-
tectable by these functional measures. There is a new
and emerging concept of subclinical acute kidney injur-
y—injury not detected by functional criteria, but through
measurement of biomarkers associated with tubular
necrosis [23].
NGAL as a Biomarker of Subclinical Acute Kidney Injury
NGAL is a small 25 kDa protein of the lipocalin family,
and was first identified by transcriptome analysis of the
murine model, investigating the early induction of gene
expression after renal ischaemia. Its expression was
found to be upregulated in tubular cells after ischaemic
injury [24]. NGAL levels have been shown to increase in
both blood and urine in response to subclinical acute
kidney injury [23, 25].
In an evaluation of 125 specimens from healthy indi-
viduals using the Alere Triage® CardioRenal Panel, it was
found that the 95th percentile upper limit was 153 ng/
mL. A study to determine the clinical utility of this com-
pared the NGAL level of 494 plasma samples from pa-
tients in intensive care with the standard RIFLE criteria
for acute kidney injury. AUC was 0.83 and a positive test
threshold of 150 ng/mL yielded a sensitivity of 0.86 and
specificity of 0.62 [26]. It was therefore shown to be a
sensitive marker of disease.
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There has been wide variation in reports of the diag-
nostic accuracy of NGAL, including variation in the
specificities reported. This may be in part as a result of
the different populations studied. NGAL is also pro-
duced by activated neutrophils and therefore may be
raised in infection or inflammation [24, 25]. Plasma
NGAL levels have been shown to be raised in septic ICU
patients without acute kidney injury, and therefore
plasma NGAL should be used with caution in this popu-
lation [27]. As our population of interest is healthy, stud-
ies looking at populations outside a critical care setting
are likely to be more generalizable to our population.
Other studies, using the point of care Triage® NGAL
Device, have demonstrated superior diagnostic accur-
acies. For example, 2-h plasma NGAL measurement of
120 children who underwent cardiopulmonary by-pass
obtained AUC of 0.96 and the same AKI threshold of
150 ng/ml yielded a sensitivity 0.84 and specificity of
0.94 [28]. Several other studies have also confirmed the
usefulness of these bedside NGAL assays in the clinical
setting [29]. Therefore, conclusions drawn from previous
studies support the diagnostic accuracy of this method.
In the living donor population, Yoon et al. demon-
strated that perioperative plasma NGAL in living donors
correlates with 6 month donor eGFR. This correlation
was found to be strongest using plasma NGAL at 1 week
post-operatively, but a correlation was found at all time
points [30].
Pilot Data
Pilot data obtained at our study centre involving 20 do-
nors indicate that hand-assisted laparoscopic nephrec-
tomy is associated with significant subclinical acute
kidney injury, defined as plasma NGAL >153 ng/ml, and
that preoperative fluids may reduce the incidence of this.
In a non-randomised pilot series, where fluids were ad-
ministered as per surgeon preference, there was found
to be an incidence of subclinical acute kidney injury of
approximately 50% in patients receiving <1000 ml of
intravenous fluids compared with a 20% incidence in
those receiving >2500 ml of intravenous fluids. An in-
verse correlation between increase in NGAL and post
donation eGFR at 6 weeks was also demonstrated [31].
The risk of subclinical acute kidney injury has been
demonstrated by Hasse et al. who analysed pooled
data from ten prospective observational studies, in-
volving over 2000 patients with cardiorenal syndrome
type 1. Subclinical acute kidney injury detected by
NGAL was found to increase the risk of adverse out-
comes, such as need for renal replacement therapy,
hospital mortality, and duration of hospital stay, even
in the absence of a diagnostically significant increase
in serum creatinine [32].
Any decrease in subclinical acute kidney injury is
therefore likely to be beneficial. In the long term, it may
result in a small increase in GFR, which may be benefi-
cial for the remaining donor function, and reduced
haemodynamic stress on the donated kidney may poten-
tially result in greater longevity of the allograft. There-
fore optimisation of perioperative fluid management is
likely to have a protective role.
Fluids in Transplant Optimization
There is some controversy surrounding perioperative
fluid administration, and optimal fluid balance. The risks
of restrictive fluid administration include inadequate
organ perfusion and post-operative nausea, whereas lib-
eral fluid use may increase the risk of prolonged post-
operative ileus, poor wound healing and the potential
for fluid overload leading to heart failure [33, 34].
There have been variable findings in this field, with
some studies demonstrating benefit from liberal fluid ad-
ministration [35–37], and others demonstrating either
deleterious effects or no difference in outcome [38].
There is some suggestion that in “low-risk” patients
undergoing mild to moderate surgery, a high-volume
fluid strategy is superior [39].
Our donor study population is a very healthy one, and
all perioperative complications will be closely monitored
for and reported.
Potential mechanisms behind attenuation of subclin-
ical acute kidney injury using preoperative fluids are that
optimal hydration results in increased renal venous and
arteriolar filling, preventing collapse and congestion.
Also, increased inferior vena cava pressure may prevent
reduced venous return during pneumoperitoneum,
maintaining cardiac output. These mechanisms may also
reduce vasoconstriction caused by activation of the
renin-angiotensin-aldosterone system [40].
We have chosen to use Hartmann’s solution (com-
pound sodium lactate) preoperatively. This contains the
following electrolyte concentrations: Na+131 mmol/L, K
+ 5 mmol/L, HCO3
− 29 mmol/L, Cl− 111 mmol/L and
Ca2 2 mmol/L [41]. Although there is some concern
about the possibility of chloride increasing the incidence
of AKI, Hartmann’s solution is considered to be a
chloride-restrictive intravenous fluid [42].
There have been few studies of donor perioperative
fluids in laparoscopic nephrectomy. Intraoperative fluid
restriction was associated with a lower urine output, but
no difference in post-operative serum creatinine levels
or complications [43]. This may be because hydration
after the establishment of pneumoperitoneum is too
late to attenuate any haemodynamic effects. Donors
given preoperative fluid were shown to be more re-
sistant to the haemodynamic compromise associated
with pneumoperitoneum [44].
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As discussed, existing studies used functional criteria,
such as serum creatinine, which detect only damage ex-
tensive enough to cause immediate functional changes,
and any subtle effects present may be masked by the
overwhelming effect of nephrectomy and subsequent
compensatory renal hypertrophy (CRH). There is there-
fore currently a lack of evidence about preoperative
fluids in laparoscopic nephrectomy, and significant vari-
ation in clinical practice. This study aims to address this.
Methods
Study Aims and Hypothesis
This study hypothesis is that the use of preoperative
intravenous Hartmann’s solution will result in a decrease
in donor subclinical acute kidney injury, defined as
plasma NGAL >153 ng/ml.
The primary aim of this study is to determine whether
preoperative intravenous fluids result in a decrease in
donor subclinical acute kidney injury. The secondary
aims include investigating the effects of fluids on various
donor and recipient clinical and biochemical outcomes,
listed below.
Study Design
This study proposes that donors will be randomised to
one of two groups: one group will receive active pre-
hydration with three litres of intravenous Hartmann’s
solution between midnight and 8 am before morning do-
nation with unlimited oral fluid as desired, while the
other group will receive just unlimited oral fluids until
midnight.
Primary Outcome
The primary outcome will be the incidence of donor
acute kidney injury (as defined by plasma NGAL
>153 ng/ml) on day 1 post-operatively.
Secondary Outcomes
 Day 1 change in donor plasma NGAL from baseline
 Donor renal function (serum creatinine and eGFR)
day 1–4, week 6 and 1 year, as is standard procedure
 Donor BNP changes
 Recipient change in plasma NGAL from baseline
 Recipient serum creatinine and eGFR at 6 weeks and
1 year
 Delayed graft function (DGF)—defined as use of
dialysis in the first week postoperatively
 1 year graft and patient survival in recipient
 Donor intraoperative haemodynamics, including
blood pressure, heart rate, stroke volume index,
cardiac index and systemic vascular resistance index
(collected from non-invasive cardiac output
monitor).
 NGAL levels in blood obtained from renal vein
during retrieval and implantation surgery
 Donor and recipient perioperative mortality
 Donor perioperative fluid balance
 Donor fluid boluses and response to fluid challenge.
 Donor and recipient perioperative complications
(including cardiorespiratory complications, time to
first bowel motion, infective complications, length of
hospital stay, readmission)
 Donor sleep quality, assessed using the Richards–
Campbell Sleep Questionnaire [45]
Inclusion criteria
 Adult patients aged >18 years of age. undergoing live
donor hand-assisted laparoscopic nephrectomy
eligible to participate
 Consent to participate given
 English-speaking or appropriate translation facilities
to allow for consent to be valid
 Laparoscopic nephrectomy taking place at the study
site
 Transplant taking place between dates of the trial.
Exclusion criteria
 Patients undergoing open nephrectomy
 Patient unable or unwilling to consent
Power Calculation to Determine Sample Size
Based on the observational pilot data discussed above,
which demonstrated a 50% incidence of day 1 subclinical
acute kidney injury in patients receiving <1000 ml of
intravenous fluids and a 20% incidence of acute kidney
injury (AKI) in patients receiving >2500 ml of intraven-
ous fluids, we anticipate that 39 patients would be re-
quired in each arm to detect a similar magnitude of
difference with 80% power and a significance level of
0.05. Allowing for 10% attrition, we intend to recruit a
total of 86 patients.
Patient Recruitment and Consent
Patients who fit the stated inclusion and exclusion cri-
teria will be identified at the time of allocation of a date
for surgery. The recruitment process will involve ap-
proaching potential participants prior to surgery, and
obtaining written consent upon hospital admission
[Fig. 1].
Randomisation and study groups
A computer-generated 1:1 allocation sequence will be
created by an independent operator who is not directly
involved with the study. Allocation concealment will be
achieved using sequentially numbered sealed opaque
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envelopes. Allocation to treatment arms will be per-
formed by a member of the research team on the day
prior to surgery, after the patient has provided valid
written consent.
Blinding
This sort of intervention means that blinding of patients
and clinicians is not feasible. Therefore a single-blind
approach is being used, where the researcher will be
blinded to the fluid hydration status of the patient at the
time of data collection.
Intervention Group
The evening prior to surgery (day-1), between midnight
and 8 am, patients in the intervention group will receive
three litres of IV Hartmann’s solution. Patients in this
group will also be admitted on the evening prior to sur-
gery (day −1) but will not be given intravenous fluids.
Both will receive unrestricted oral fluids in line with the
European Society of Anaesthesiology perioperative fast-
ing guidelines and will be encouraged to drink freely. It
will be ensured that both groups have ready and equal
access to unrestricted oral fluids, and any oral and intra-
venous fluid intake will be recorded via routine fluid
charts.
Pre-operative management
All patients will be admitted on the afternoon prior to
surgery as is routine practice and receive entirely stand-
ard care in all ways other than the different pre-surgical
fluid regimes indicated in this protocol.
Intra-operative management
All patients will receive standard anaesthetic care and
monitoring. Additionally, in order to obtain key haemo-
dynamic measurements, such as cardiac index (CI), sys-
temic vascular resistance index (SVRI) and stroke
volume index (SVI) measurements, the use of a non-
invasive cardiac output monitor will be required. The
NICCOMO™ bioimpedance system (Medis, Germany)
will be used—a novel and totally non-invasive monitor
which employs impedance cardiography to measure car-
diac output. It does so by measuring electrical signals
produced by changes in the volume and velocity of the
blood in the thoracic aorta. This NICCOMO system is
complemented by another device—the CNAP™ Monitor
500 (CNSystems, Austria). The CNAP Monitor employs
the volume-clamp method of Penaz to measure non-
invasive arterial blood pressure continuously via two
small inflatable cuffs applied to the fingers of one hand.
The cardiac output monitor will be attached to the
Identification of a donor undergoing laparoscopic 
nephrectomy who fits the stated inclusion and 
exclusion criteria.
A letter sent to the patients, 
explaining the purpose of the study 
and containing the relevant 
Participant Information Sheet (PIS).
Personal communication of study 
details by a member of the 
research team prior to admission 
for surgery plus provision of PIS.
On admission for surgery, a member of the research team 
will review the details of the study with the patient and what 
participation would involve. 
The Participant Information Sheets will be reviewed and 
discussed with the patients.
After the patients have had sufficient time to consider 
participation in the study, a member of the research team will 
ensure they understand what the study involves and answer 
any questions, allowing extra time for questions if needed. 
If the patients consent to participate in the study, this will be 
documented using the Donor and Recipient consent forms 
respectively.
Fig. 1 Participant Recruitment Flow Diagram. A diagram showing the ways in which potential participants will be approached and
consent will be obtained
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patient shortly after the induction of anaesthesia and will
remain in situ throughout the surgical procedure. It will
be removed at the end of the operation before the pa-
tient is transferred to the recovery room. The anaesthe-
tist will be blinded to the results of the cardiac output
monitor.
The cardiovascular response to a single 500 ml fluid
challenge will be assessed following the induction to an-
aesthesia. Cardiovascular parameters with be recorded,
then a “stat” 500 ml fluid challenge will be administered
and cardiovascular parameters recorded again. Again,
the anaesthetist will be blinded to the results of this
challenge.
Additionally a single 5 ml sample of venous blood will
be obtained from the donor renal vein immediately after
retrieval and immediately after implantation to assess
the immediate impact on biomarkers of AKI.
Postoperative management
After surgery, patients will be taken to the recovery
room and monitored according to standard hospital pol-
icy before return to the transplant ward for post-
operative care.
Patients will receive their normal medications prior to
surgery unless otherwise directed by the anaesthetist.
Criteria for discontinuation
Every effort will be made to retain patients in the trial
and to minimise withdrawals. Patients with capacity to
consent may request to be withdrawn from this study at
any time. If the patient develops a severe or life-
threatening condition and loses capacity, continued
consent will be presumed unless it is deemed that con-
tinuation of the trial will result in an adverse outcome
for the patient. This is because follow-up of patients
who have complications is particularly important for this
trial, as it is examining the effect that preoperative intra-
venous fluid has on these.
In patients who do withdraw from the study, reasons
for withdrawal will be documented. All data accumu-
lated up to the time of withdrawal will be retained and
included in subsequent statistical analyses.
Study Centre
The study will be conducted solely within the West of
Scotland Renal Transplant Unit. Follow-up will be under-
taken in out-patient clinics throughout NHS Greater
Glasgow and Clyde by the Renal Transplantation Team.
Data Collection
Data will be obtained from the ward observation and
fluid charts, anaesthetic record, recovery room observa-
tion chart, laboratory and bedside blood test results, in-
traoperative data collection and clinical review in the
post-operative period. To avoid any bias, the outcome
assessor will be blinded to the fluid hydration that the
patient received. The data that will be collected includes
demographic data, patient details, perioperative details
and primary and secondary outcome data [Table 1].
Data Management
Data will be entered on a patient-by-patient basis into a
computerised password-protected database on a com-
puter within the Department of Renal Transplantation
by an investigator blinded to the study group allocation.
Patients will be identified by their study number only.
After data analysis has been performed, it will be com-
bined with the randomisation code and the nature of
each patient’s perioperative fluid regimen will be re-
vealed. This will be performed in accordance with the
Data Protection Act. A case report file will be created
for each patient. These will be archived in a locked facil-
ity and kept for a period of 3 years.
Table 1 Data to be collected
Donor and Recipient
Demographic Data
Age
Gender
Ethnicity
Weight
Body mass index
Recipient Details Comorbidities
Indication for transplant
Perioperative Details Volume of donor fluid intake—oral and
intravenous
Preoperative donor urine output
Intraoperative donor urine output
Donor fluid boluses and response to fluid
challenge.
Surgeon performing the operation
Duration of surgery
Cold and warm ischaemic times
Primary and
Secondary Outcome
Data
Donor NGAL and BNP (4 measurements):
preoperative (day −1), immediately preoperative
(day 0), immediately postoperative (day 0),
postoperative
(day +1)
Recipient NGAL (3 measurements): preoperative
(baseline), immediately post-operative,
postoperative
(day +1).
Donor eGFR: days 1–4, week 6 and 1 year
Recipient eGFR: week 6 and 1 year
Recipient delayed graft function (DGF)—defined
as use of dialysis in the first week postoperatively
1 year graft and patient survival in recipient
Donor intraoperative haemodynamics (including
blood pressure, heart rate, stroke volume index,
cardiac index and systemic vascular resistance).
Biomarkers of AKI, including N-GAL, KIM-1
and leukocyte subsets, in blood obtained from
renal vein during retrieval and implantation surgery
Donor and recipient perioperative mortality
Donor and recipient perioperative complications
(including cardiorespiratory complications, time to
first bowel motion, infective complications,
length of hospital stay, readmission)
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Statistical Analysis
Descriptive statistics will be used to describe continuous
variables. Results for continuous variables will be re-
ported as mean (+/− standard deviation) or median
(interquartile range). The primary outcome, proportion
of patients in each group with subclinical acute kidney
injury, will be compared using a chi-square test and 95%
confidence intervals for the difference in proportions.
If the data for continuous variables follow a Normal
distribution, the variables will be compared using a
Student’s t-test. If data are found to not be Normally dis-
tributed, a Mann Whitney U-test will be used. Analysis
will be performed on an intention-to-treat basis.
Study reporting will be in accordance with the CON-
SORT guidelines.
Discussion
As there is currently relatively little data about preopera-
tive fluid use in laparoscopic donor nephrectomy, it is
hoped that this study will provide important clinical
information. Prior to this study, trials looking at pre-
operative fluids have shown a beneficial effect on intra-
operative haemodynamics. In this study, plasma NGAL
will be used to determine whether this effect translates
to a reduction in subclinical acute kidney injury, which
may be of benefit for both the donor and the recipient.
In terms of the volume of intravenous fluid adminis-
tration, Mertens zur Borg et al. based the volume of
fluid administered on ideal body weight [44]. Though
this is a useful approach in terms of monitoring the rela-
tive effects of fluid on patient physiology, it was decided
that in this study a pragmatic approach to this would be
the most feasible option. As approximately 3 L of intra-
venous fluid has been administered preoperatively previ-
ously, it was decided that this volume would be used.
This is useful both in terms of facilitating adherence to
the protocol and in terms of potential future clinical
utility, as it would be more easily reproduced in future
clinical practice, should any clinical benefit be found.
It is hoped that, whatever the findings of the study, the
results will be of real clinical relevance. If preoperative
intravenous fluids are found to be of benefit, then this
could lead to their widespread use in clinical practice. If,
however, no difference is found between the groups,
then live donors may not need be admitted to hospital
until the morning of the surgery which would mean
greater patient convenience and reduced costs.
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